Skip to content
The Nexus
DossierENTITY

Replimune

Coverage of Replimune in the Nexus archive.

Earliest in view: Apr 13 · 11:54 UTCMost recent: May 15 · 09:00 UTC
Co-mentioned in this coverage
Marty Makaryperson1Food and Drug Administration (FDA)organization1Trisha Wise-Draperperson1Eric Whitmanperson1Robert F. Kennedy Jr.person1Donald Trumpperson1Baker Hughesorganization1Goldman Sachsorganization1Leggettorganization1New York Stock Exchangeplace1
Recent coverage
  • HEALTHMay 15 · 09:00 UTCKFF HEALTH NEWS
    FDA Blocked Melanoma Drug as Confusion Reigned Under Makary

    The FDA's decision to withhold approval of a new skin cancer treatment has been met with criticism from doctors and patients, with some citing concerns about the agency's changed culture under Commissioner Marty Makary. The treatment, called RP1, had shown promise in prolonging the lives of some patients. The FDA's decision has raised questions about the agency's standards and processes.

  • BUSINESSApr 13 · 11:54 UTCBLOOMBERG
    US Premarket Movers: Baker Hughes, Goldman, Leggett, Replimune

    The article highlights premarket stock movements involving Baker Hughes, Goldman Sachs, Leggett, and Replimune. It mentions Goldman Sachs' signage at the New York Stock Exchange floor, indicating market activity.